Biotron Limited · ASX:BIT
Biotron — Shareholder Meeting (November 2017)
19 slides from Biotron's shareholder meeting presentation, Nov 20, 2017
Slide 1: Presentation to Annual General Meeting cover letter
Level 2, 666 Hunter Strreet Syd dney NSW 22000 For personal use only Tel: (61-2) 9300 3344 Fax: (61-2) 9221 66333 E-mail: p pnightingale@ @biotron.com m.au W Website: www w.biotron.comm.au 20 Novembber 2017 The Managger Compannies ASX Limitted 20 Bridge S Street SYDNEY NSW 20000 (19 ppages by em mai
Slide 2: Chairman's Address to the AGM
Level 2, 666 Hunter Strreet Syddney NSW 22000 For personal use only Tel: (61-2) 9300 3344 Fax: (61-2) 9221 66333 E E-mail: info@ @biotron.com m.au W Website: wwww.biotron.comm.au 20 Novembber 2017 w Shareholdeers My Fellow CH HAIRMAN’S ADDRES SS TO THE E AGM In recent w weeks, Biotroon has takenn a
Slide 3: Chairman's Address (continued)
In particular, I should single out Denis Wade for his enduring contribution and dedication to the Company since he joined the Board in 2010. For personal use only For personal reasons, Denis steps down from the Board today. Denis' advice and insight have been of enormous value to me personally and t
Slide 4: For personal use only
For personal use only Slide 'tle
Slide 5: Forward Looking Statements
Forward Looking Statements For personal use only This presenta'on may contain forward looking statements with respect to the financial condi'on, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objec'ves of its management. These statement
Slide 6: Investment Highlights
Investment Highlights For personal use only • Biotron is designing, developing and commercialising a plaUorm of an'viral drugs with a novel mode of ac'on – able to target a wide variety of viral infec'ons • Pipeline of programs in high value, high need markets • Progress in clinical lead program (BI
Slide 7: Biotron Limited – Snap Shot
Biotron Limited – Snap Shot For personal use only BROAD PLATFORM WITH NEW CLASS OF ANTIVIRAL DRUGS HIV-1 ERADICATION HEPATITIS C VIRUS (HCV) HBV & EARLY STAGE PROGRAMS - Targe'ng HIV-1 in long-lived - New class of HCV drug - Pipeline of early stage reservoirs - Phase 2 completed programs, including:
Slide 8: Key Achievements FY 2017
Key Achievements FY 2017 For personal use only • Commenced Phase 2 clinical trial of BIT225 and Combina'on An'retroviral Therapy (cART) in Feb’17 • Fully recruited in July ‘17; Dosing with BIT225/placebo completed; data pending • Demonstrated significant and accelerated reduc'on in HIV-1 viral load f
Slide 9: Commercialisation – Key Focus
CommercialisaUon – Key Focus For personal use only • Three tac'cal priori'es: • Partnering lead clinical program - BIT225 for HIV-1 eradica'on • Partnering one or more preclinical programs – e.g. HBV • Execute a regional licensing deal in China - HCV program remains a great opportunity
Slide 10: HIV-1 Eradication
HIV-1 EradicaUon Current drugs do not eradicate HIV-1 virus For personal use only • HIV-1 remains hidden in reservoirs, leading to chronic, life-long infec'on • Invisible to body’s immune defenses • Not sensi've to an'-HIV-1 drugs • New mode of ac'ons drugs are needed to eradicate or cure HIV-1 infe
Slide 11: HIV-1 Eradication: BIT225-009 Trial
HIV-1 EradicaUon: BIT225-009 Trial For personal use only BIT225 or placebo added to ART • 36 HIV-1+ve, treatment-naïve subjects commencing ART • Randomised 2:1 (drug:placebo) • BIT225 or placebo added to ART for first 12 weeks of treatment • Read-out • Impact on virus levels; reduc'on of immune ac'va
Slide 12: HIV-1 Eradication: BIT225-009 Trial
HIV-1 EradicaUon: BIT225-009 Trial For personal use only • Fully recruited July; last pa'ent, last dose in mid-October • Three month follow-up period post-dosing with BIT225/placebo • Addi'onal samples collected from pa'ents throughout this next 3 month period • Post-trial laboratory analyses on sam
Slide 13: Commercialisation: BIT225 HIV-1 Eradication
CommercialisaUon: BIT225 HIV-1 EradicaUon For personal use only • Several pharmaceu'cal companies have ac've HIV-1 “Cure” Programs • Iden'fied and qualified poten'al partners • Posi've outcomes – BIT225 clinical trial - key to progressing commercialisa'on discussions • Poten'al partners have defined th
Slide 14: Commercialisation: Preclinical Programs – HBV
CommercialisaUon: Preclinical Programs – HBV For personal use only • Hepa''s B virus (HBV) therapeu'c space has significant interest from pharma & biotech companies • Biotron’s HBV program is elici'ng early interest from poten'al partners • In vitro data on several candidate compounds includes eviden
Slide 15: Commercialisation: Regional Licensing – China, HCV Program
CommercialisaUon: Regional Licensing – China, HCV Program For personal use only • The new HCV drugs (e.g. Solvadi) may cause reac'va'on of HBV in HCV/HBV coinfected pa'ents • Resulted in US FDA “Black Box” Warning on new HCV drugs • 30 million HCV-infected people in China, compared to 3-5 million in
Slide 16: Commercialisation: Regional Licensing – China, HCV Program
CommercialisaUon: Regional Licensing – China, HCV Program For personal use only • Seeking partnerships for commercialisa'on of BIT225 for the treatment of HCV in China • Appointed a Shanghai-based corporate advisor with extensive experience in cross-border transac'ons in the healthcare space • Devel
Slide 17: Unlocking Value for Other Virus Targets
Unlocking Value for Other Virus Targets For personal use only Library of compounds designed to target viroporins found in some viruses: Ini'ally >250 compounds designed and synthesised; library now ~350 OTHER “HITS” IN LIBRARY include: • Influenza A and B • Hepa''s B virus (HBV) • Coronaviruses (Incl
Slide 18: Unlocking Value for Other Virus Targets
Unlocking Value for Other Virus Targets For personal use only Biotron’s Viroporin approach enables the targe'ng of a wide range of viral diseases; examples include: • Respiratory Viruses such as Respiratory Syncy'al Virus (RSV), Influenza, & Coronaviruses (leading cause of “common cold”) • Flavivirus
Slide 19: Summary
Summary For personal use only • HIV EradicaUon • Engaged with the right poten'al partners • Wai'ng for data from trial but con'nue to engage with pharma • Preclinical Programs • HBV has promise as a preclinical candidate for joint development. HBV therapeu'c space is very hot. • BIT225 results valid